# CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

Study · id `cardio:ct-nct02579096` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02579096](<https://clinicaltrials.gov/study/NCT02579096>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02579096

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 950 participants.

## Technical summary

Registry record NCT02579096. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-06 (actual); primary completion 2021-02-01 (actual). Results posted on 2022-01-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 950 participants (enrolled count; ClinicalTrials.gov record NCT02579096, source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)
- Started: 2017-03-06 (actual) (ClinicalTrials.gov record NCT02579096, source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)
- Primary completion: 2021-02-01 (actual) (ClinicalTrials.gov record NCT02579096, source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)
- Completion: 2021-04-15 (actual) (ClinicalTrials.gov record NCT02579096, source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)
- Results first posted: 2022-01-11 (ClinicalTrials.gov record NCT02579096, source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02579096, source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02579096-2024-03-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
- Condition: Gout
- Condition: Chronic Kidney Diseases
- Intervention (Drug): allopurinol capsule, 100-800 mg by mouth once daily
- Intervention (Drug): febuxostat tablet 40-120 mg by mouth once daily
- Intervention (Drug): Placebo, vehicle control (febuxostat-shaped)
- Intervention (Drug): Placebo, vehicle control (allopurinol-shaped)
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout (`cardio:pubmed-37842953`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators (`cardio:pubmed-39426967`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 09e9053fa47d311e59c61bd72d478f499c22fcc702a1cf72af6362a99b1a68be
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
